**
A groundbreaking vaccine administered during pregnancy is proving to be a game-changer in the fight against respiratory syncytial virus (RSV), significantly reducing hospital admissions for newborns by over 80%. This remarkable development, confirmed by UK health officials, offers crucial protection against a virus that poses serious health risks to infants in their first months of life.
The Burden of RSV on Newborns
RSV is a common virus that can lead to severe respiratory infections in young children, with over 20,000 infants in the UK requiring hospital care each year. The virus can manifest in symptoms ranging from mild cold-like signs to severe breathing difficulties that may necessitate oxygen support. Tragically, a small number of infants do not survive the complications associated with RSV.
Dr Conall Watson, the national programme lead for RSV at the UK Health Security Agency (UKHSA), outlined the distressing reality for families affected by the virus. “In babies with severe infections, you can visibly see them struggling to breathe, which is understandably terrifying for parents,” he stated, highlighting the urgency of protecting this vulnerable population.
The Introduction of the Vaccine
In 2024, the UK introduced a vaccine aimed at pregnant women, recommended from 28 weeks gestation onwards. This development was prompted by clinical trials demonstrating that the vaccine enhances the mother’s immune response, allowing for the transfer of protective antibodies to the unborn child via the placenta.
Recent research assessing the vaccine’s effectiveness involved nearly 300,000 births in England between September 2024 and March 2025, representing about 90% of all births in that period. The study found that when administered at least four weeks before delivery, the vaccine provided nearly 85% protection against RSV for newborns. Notably, even if the vaccine is given closer to the birth, some level of protection can still be conferred, suggesting that timely vaccination is crucial but not the sole determining factor in safeguarding infants.
Encouraging Vaccination Uptake
Despite the promising results, vaccination rates among pregnant women remain a concern. Current figures indicate that approximately 64% of expectant mothers in England are receiving the RSV vaccine, with the uptake dropping to 53% in London. This discrepancy raises questions about accessibility and awareness in different regions.
Dr Watson urges pregnant women to consider the vaccine seriously. “I would strongly encourage any pregnant woman to discuss it with their midwife and be ready to have the vaccine at their 28-week appointment, or arrange another appointment shortly thereafter,” he advised.
Personal Stories Highlight Vaccine Importance
The importance of this vaccine is underscored by personal accounts from families affected by RSV. One poignant story is that of Laine Lewis, whose son Malachi faced severe complications from RSV after his birth. Although he was not vaccinated in time, Laine advocates for the vaccine, emphasising its potential to prevent similar tragedies. “I’d encourage people to take the vaccine for RSV because it will help their child,” she stated, highlighting the importance of awareness and proactive health measures.
Why it Matters
The introduction of the RSV vaccine for pregnant women represents a significant advancement in public health, particularly for vulnerable newborns. With the potential to drastically reduce hospital admissions and serious health complications from RSV, the vaccine not only protects individual infants but also alleviates the broader strain on healthcare systems during peak respiratory virus seasons. Ensuring high vaccination rates among expectant mothers is essential for maximising these benefits and safeguarding the health of the next generation.
